While reporting financial results for the fourth quarter on Wednesday, biopharmaceutical company AbbVie, Inc. (ABBV) initiated its adjusted earnings guidance for the full-year 2026, above analysts' estimates.
For fiscal 2026, AbbVie now projects adjusted earnings in a range of $14.37 to $14.57 per share, which excludes any impact from acquired IPR&D and milestones expense.
On average, 27 analysts polled expect the company to report earnings of $14.22 per share for the year. Analysts' estimates typically exclude special items.
For the fourth quarter, the company reported net earnings attributable to AbbVie of $1.82 billion or $1.02 per share, compared to $22 million or $0.02 per share in the prior-year quarter.
Excluding items, adjusted earnings for the quarter was $2.71 per share, compared to $2.16 per share in the year-ago quarter.
Net revenues for the quarter grew to $16.62 billion from $15.10 billion in the same quarter last year.
The Street was looking for earnings of $2.65 per share on revenues of $16.42 billion for the quarter.
In Wednesday's pre-market trading, ABBV is trading on the NYSE at $218.49, down $7.13 or 3.16 percent.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.